我省全链条支持创新药高质量发展

Group 1 - The core viewpoint emphasizes the importance of encouraging the development of innovative drugs to enhance clinical medication technology and improve public health, while also supporting the self-reliance and technological innovation of the biopharmaceutical industry [1] - The provincial medical insurance bureau and health committee have jointly issued a notice to support high-quality development of innovative drugs across the entire chain, aiming to better meet the public's needs for disease prevention, treatment, and medication [1] - The notice outlines measures to support the inclusion of innovative drugs in the basic medical insurance drug list and to establish a dynamic adjustment mechanism for this list based on the capacity of the insurance fund and clinical advancements [1] Group 2 - Local medical insurance and health departments are required to focus on key issues and develop targeted measures to ensure effective implementation of policies, including evaluating the impact of support measures [2] - There is an emphasis on improving data sharing and monitoring related to drug usage among relevant departments to provide data support for dynamically improving policies that support innovative drug development [2] - To strengthen fund supervision, local areas are encouraged to innovate regulatory methods, enhance big data analysis, and integrate online and offline inspections to combat fraud in medical insurance [2]